Citations

Mayo Clinic

Clear

1941 citation(s) found for "Ruíz, Carlos".

Outcomes of Severe Sepsis and Septic Shock Patients on Chronic Antiplatelet Treatment: A Historical Cohort Study
Valerio-Rojas, Juan Carlos , Jaffer, Insara J., Kor, Daryl J. , Cartin‐Ceba, Rodrigo , Gajic, Ognjen

Critical Care Research and Practice | February 20, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-9

10.1155/2013/782573 | PMID 23509620 Get It

Background. Sepsis is characterized by dysfunctional activation of platelets, and antiplatelet therapy could improve the outcomes of septic patients.Methods. We performed a retrospective cohort study of severe sepsis or septic shock adult patients. Outcomes of patients on antiplatelet therapy were compared to those that were not taking antiplatelet therapy by univariate analysis followed by a propensity score analysis based on the probability of receiving antiplatelet therapy.Results. Of 651 patients included in the study 272 (42.8%) were on antiplatelet therapy before the development of severe sepsis or septic shock. After adjusting for important confounding variables antiplatelet therapy was not associated with a decreased risk of hospital mortality (odds ratio 0.73, 95% confidence interval 0.46–1.16). Antiplatelet therapy was associated with a decreased incidence of acute respiratory distress syndrome/acute lung injury (odds ratio 0.50, 95% confidence interval 0.35–0.71) and reduced need of mechanical ventilation (odds ratio 0.62, 95% confidence interval 0.45–87). Incidence of acute kidney injury was similar between both groups (odds ratio 1.08, 95% confidence interval 0.73–1.59).Conclusions. The use of antiplatelet therapy before the diagnosis of severe sepsis or septic shock was not associated with decreased hospital mortality. Antiplatelet therapy was associated with a decreased incidence of acute lung injury/acute respiratory distress syndrome.
Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force
Frey, Benício N. , Andreazza, Ana C. , Houenou, Josselin , Jamain, Stéphane , Goldstein, Benjamin I. , Frye, Mark A. , Leboyer, Marion , Berk, Michael , Malhi, Gin S. , López‐Jaramillo, Carlos , Taylor, Valerie H. , Frangou, Sophia , Hall, Geoffrey B. , Fernandes, Brisa S. , Kauer‐Sant’Anna, Marcia , Yatham, Lakshmi N. , Kapczinski, Flávio , Young, L. Trevor , Dodd, Seetal , Andreazza, Ana C , Frangou, Sophia , López-Jaramillo, Carlos , Yatham, Lakshmi N , Jamain, Stéphane , Leboyer, Marion , Berk, Michael , Malhi, Gin S , Goldstein, Benjamin I

Australian & New Zealand Journal of Psychiatry | February 15, 2013 | Volume: 47 | Issue: 4 | Pages: 321-332

10.1177/0004867413478217 | PMID 23411094 Get It

Although the etiology of bipolar disorder remains uncertain, multiple studies examining neuroimaging, peripheral markers and genetics have provided important insights into the pathophysiologic processes underlying bipolar disorder. Neuroimaging studies have consistently demonstrated loss of gray matter, as well as altered activation of subcortical, anterior temporal and ventral prefrontal regions in response to emotional stimuli in bipolar disorder. Genetics studies have identified several potential candidate genes associated with increased risk for developing bipolar disorder that involve circadian rhythm, neuronal development and calcium metabolism. Notably, several groups have found decreased levels of neurotrophic factors and increased pro-inflammatory cytokines and oxidative stress markers. Together these findings provide the background for the identification of potential biomarkers for vulnerability, disease expression and to help understand the course of illness and treatment response. In other areas of medicine, validated biomarkers now inform clinical decision-making. Although the findings reviewed herein hold promise, further research involving large collaborative studies is needed to validate these potential biomarkers prior to employing them for clinical purposes. Therefore, in this positional paper from the ISBD-BIONET (biomarkers network from the International Society for Bipolar Disorders), we will discuss our view of biomarkers for these three areas: neuroimaging, peripheral measurements and genetics; and conclude the paper with our position for the next steps in the search for biomarkers for bipolar disorder.
DBC1 (Deleted in Breast Cancer 1) modulates the stability and function of the nuclear receptor Rev-erbα
Chini, Claudia C.S. , Escande, Carlos , Nin, Verónica , Chini, Eduardo N.

Biochemical Journal | February 13, 2013 | Volume: 451 | Issue: 3 | Pages: 453-461

10.1042/bj20121085 | PMID 23398316 Get It

The nuclear receptor Rev-erbα has been implicated as a major regulator of the circadian clock and integrates circadian rhythm and metabolism. Rev-erbα controls circadian oscillations of several clock genes and Rev-erbα protein degradation is important for maintenance of the circadian oscillations and also for adipocyte differentiation. Elucidating the mechanisms that regulate Rev-erbα stability is essential for our understanding of these processes. In the present paper, we report that the protein DBC1 (Deleted in Breast Cancer 1) is a novel regulator of Rev-erbα. Rev-erbα and DBC1 interact in cells and in vivo, and DBC1 modulates the Rev-erbα repressor function. Depletion of DBC1 by siRNA (small interfering RNA) in cells or in DBC1-KO (knockout) mice produced a marked decrease in Rev-erbα protein levels, but not in mRNA levels. In contrast, DBC1 overexpression significantly enhanced Rev-erbα protein stability by preventing its ubiquitination and degradation. The regulation of Rev-erbα protein levels and function by DBC1 depends on both the N-terminal and C-terminal domains of DBC1. More importantly, in cells depleted of DBC1, there was a dramatic decrease in circadian oscillations of both Rev-erbα and BMAL1. In summary, our data identify DBC1 as an important regulator of the circadian receptor Rev-erbα and proposes that Rev-erbα could be involved in mediating some of the physiological effects of DBC1.
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome
Al‐Kali, Aref , Luthra, Raja, Bueso‐Ramos, Carlos E. , Kadia, Tapan M. , Faderl, Stefan, Cortes, Jörge E. , Tefferi, Ayalew , Kantarjian, Hagop M. , Garcia‐Manero, Guillermo , Quintás‐Cardama, Alfonso , Pierce, Sherry A. , Borthakur, Gautam , Estrov, Zeev E. , Jabbour, Elias , Ravandi, Farhad , Cortes, Jorge , Kantarjian, Hagop

American Journal of Hematology | February 8, 2013 | Volume: 88 | Issue: 5 | Pages: 365-369

10.1002/ajh.23410 | PMID 23512829 Get It

RAS is an oncogene frequently mutated in human cancer. RAS mutations have been reported in 10–15% of cases of acute myeloid leukemia (AML) but they appear to be less frequent among patients with myelodysplastic syndrome (MDS). The impact of RAS mutations in patients with MDS is unclear. We conducted a retrospective study in 1,067 patients with newly diagnosed MDS for whom RAS mutational analysis was available. Overall, 4% of patients carried mutant RAS alleles. Notably, FLT3 mutations, which were found in 2% of patients, were mutually exclusive with RAS mutations. Patients with RAS mutations had a higher white blood cell count as well as bone marrow blasts compared with patients carrying wild‐type RAS. However, no differences were observed between both groups regarding the risk of AML transformation (9% vs. 7%) and overall survival (395 days vs. 500 days, P = 0.057). In summary, RAS mutations are infrequent in patients with MDS and do not appear to negatively impact their outcome. Am. J. Hematol. 88:365–369, 2013. © 2013 Wiley Periodicals, Inc.
Diagnosis and Management of Cystic Pancreatic Lesions
Sahani, Dushyant V., Kambadakone, Avinash, Macari, Michael, Takahashi, Naoki , Chari, Suresh T. , Castillo, Carlos Fernández‐del , Takahashi, Naoki , Chari, Suresh T

American Journal of Roentgenology | January 23, 2013 | Volume: 200 | Issue: 2 | Pages: 343-354

10.2214/ajr.12.8862 | PMID 23345356 Get It

Neuromotor control in chronic obstructive pulmonary disease
Mantilla, Carlos B. , Sieck, Gary C. , Sieck, Gary , Mantilla, Carlos B

Journal of Applied Physiology | January 18, 2013 | Volume: 114 | Issue: 9 | Pages: 1246-1252

10.1152/japplphysiol.01212.2012 | PMID 23329816 Get It

Neuromotor control of skeletal muscles, including respiratory muscles, is ultimately dependent on the structure and function of the motor units (motoneurons and the muscle fibers they innervate) comprising the muscle. In most muscles, considerable diversity of contractile and fatigue properties exists across motor units, allowing a range of motor behaviors. In diseases such as chronic obstructive pulmonary disease (COPD), there may be disproportional primary (disease related) or secondary effects (related to treatment or other concomitant factors) on the size and contractility of specific muscle fiber types that would influence the relative contribution of different motor units. For example, with COPD there is a disproportionate atrophy of type IIx and/or IIb fibers that comprise more fatigable motor units. Thus fatigue resistance may appear to improve, while overall motor performance (e.g., 6-min walk test) and endurance (e.g., reduced aerobic exercise capacity) are diminished. There are many coexisting factors that might also influence motor performance. For example, in COPD patients, there may be concomitant hypoxia and/or hypercapnia, physical inactivity and unloading of muscles, and corticosteroid treatment, all of which may disproportionately affect specific muscle fiber types, thereby influencing neuromotor control. Future studies should address how plasticity in motor units can be harnessed to mitigate the functional impact of COPD-induced changes.
Is preoperative ciliary body and iris anatomical configuration a predictor of malignant glaucoma development?
Prata, Tiago S. , Dorairaj, Syril , Moraes, Carlos GV De, Mehta, Siddhart, Sbeity, Zaher, Tello, Celso , Liebmann, Jeffrey M. , Ritch, Robert , Dorairaj, Syril

Clinical & Experimental Ophthalmology | December 25, 2012 | Volume: 41 | Issue: 6 | Pages: 541-545

10.1111/ceo.12057 | PMID 23279576 Get It

AbstractBackgroundTo investigate anatomical configuration of ciliary body and iris using ultrasound biomicroscopy as a predictor of malignant glaucoma development.DesignRetrospective study in a tertiary care hospital.ParticipantsCohort of 31 consecutive patients diagnosed with post‐surgical malignant glaucoma.MethodsAnterior chamber angle, iris and ciliary body configuration of involved eyes that had ultrasound biomicroscopy evaluation prior to the malignant glaucoma onset were evaluated. In cases with no presurgical ultrasound biomicroscopy exam of the involved eye, images from the fellow eye (imaged within 6 months) were analysed.Main Outcome MeasuresQualitative parameters.ResultsThirty‐one eyes (31 patients) had confirmed malignant glaucoma between 1996 and 2008. Most patients were women (65%) and had an anatomical narrow angle or angle‐closure glaucoma (77%). Mean intraocular pressure at diagnosis was 30.4 ± 13.5 mmHg. The most common operation was trabeculectomy with mitomycin C (55%, 17/31 eyes), combined (3/17) or not (14/17) with cataract extraction and intraocular lens implantation. Among these 31 cases, we were able to evaluate the ultrasound biomicroscopy images of 13 patients (13 eyes) including involved eyes imaged prior to the malignant glaucoma onset or eligible fellow eyes. A narrow angle with or without iridotrabecular contact was found in all eyes. A large and/or anteriorly positioned ciliary body associated with an iris root angulating forward and centrally, revealing a plateau iris configuration, was noticed in 85% (11/13) of these eyes.ConclusionIdentification of plateau iris configuration by ultrasound biomicroscopy should be considered as a possible predictor of post‐operative malignant glaucoma development.
Prolonged C 2 spinal hemisection-induced inactivity reduces diaphragm muscle specific force with modest, selective atrophy of type IIx and/or IIb fibers
Mantilla, Carlos B. , Greising, Sarah M. , Zhan, Wen-Zhi, Seven, Yasin B. , Sieck, Gary C. , Sieck, Gary , Mantilla, Carlos B

Journal of Applied Physiology | November 30, 2012 | Volume: 114 | Issue: 3 | Pages: 380-386

10.1152/japplphysiol.01122.2012 | PMID 23195635 Get It

The diaphragm muscle (DIAm) is critically responsible for sustaining ventilation. Previously we showed in a commonly used model of spinal cord injury, unilateral spinal cord hemisection at C 2 (SH), that there are minimal changes to muscle fiber cross-sectional area (CSA) and fiber type distribution following 14 days of SH-induced ipsilateral DIAm inactivity. In the present study, effects of long-term SH-induced inactivity on DIAm fiber size and force were examined. We hypothesized that prolonged inactivity would not result in substantial DIAm atrophy or force loss. Adult rats were randomized to control or SH groups ( n = 34 total). Chronic bilateral DIAm electromyographic (EMG) activity was monitored during resting breathing. Minimal levels of spontaneous recovery of ipsilateral DIAm EMG activity were evident in 42% of SH rats (<25% of preinjury root mean square amplitude). Following 42 days of SH, DIAm specific force was reduced 39%. There was no difference in CSA for type I or IIa DIAm fibers in SH rats compared with age, weight-matched controls (classification based on myosin heavy chain isoform expression). Type IIx and/or IIb DIAm fibers displayed a modest 20% reduction in CSA ( P < 0.05). Overall, there were no differences in the distribution of fiber types or the contribution of each fiber type to the total DIAm CSA. These data indicate that reduced specific force following prolonged inactivity of the DIAm is associated with modest, fiber type selective adaptations in muscle fiber size and fiber type distribution.
Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38
Escande, Carlos , Nin, Verónica , Price, Nathan L. , Capellini, Verena Kise , Gomes, Ana P., Barbosa, Maria Thereza , O’Neil, Luke, White, Thomas A. , Sinclair, David , Chini, Eduardo N. , Sinclair, David A

Diabetes | November 20, 2012 | Volume: 62 | Issue: 4 | Pages: 1084-1093

10.2337/db12-1139 | PMID 23172919 Get It

Metabolic syndrome is a growing health problem worldwide. It is therefore imperative to develop new strategies to treat this pathology. In the past years, the manipulation of NAD+ metabolism has emerged as a plausible strategy to ameliorate metabolic syndrome. In particular, an increase in cellular NAD+ levels has beneficial effects, likely because of the activation of sirtuins. Previously, we reported that CD38 is the primary NAD+ase in mammals. Moreover, CD38 knockout mice have higher NAD+ levels and are protected against obesity and metabolic syndrome. Here, we show that CD38 regulates global protein acetylation through changes in NAD+ levels and sirtuin activity. In addition, we characterize two CD38 inhibitors: quercetin and apigenin. We show that pharmacological inhibition of CD38 results in higher intracellular NAD+ levels and that treatment of cell cultures with apigenin decreases global acetylation as well as the acetylation of p53 and RelA-p65. Finally, apigenin administration to obese mice increases NAD+ levels, decreases global protein acetylation, and improves several aspects of glucose and lipid homeostasis. Our results show that CD38 is a novel pharmacological target to treat metabolic diseases via NAD+-dependent pathways.
Use and Interpretation of Composite End Points in Orthopaedic Trials
Busse, Jason W. , Bhandari, Mohit , Ferreira‐González, Ignacio , Montori, Víctor M. , Guyatt, Gordon , Montori, Victor M

Journal of Bone and Joint Surgery | November 15, 2012 | Volume: 94 | Issue: Supplement_1 | Pages: 65-69

10.2106/jbjs.k.01287 | PMID 22810451 Get It

Abstract: Randomized controlled trials in orthopaedics are often underpowered to detect important differences in outcomes. Composite end points (CEPs) hold promise as a strategy to address this issue by combining multiple end points into one summary measure, thus increasing the observed event rate. The use of CEPs by trialists, however, can be problematic when they include components that vary greatly in importance to patients and when differences in apparent effect between components are large. We present an overview of CEPs with a focus on appropriate design and interpretation of results.